Kadmon Holdings, Inc. (KDMN)
(Delayed Data from NYSE)
$2.33 USD
+0.08 (3.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $2.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.33 USD
+0.08 (3.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $2.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Kadmon Holdings, Inc. (KDMN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 3393.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Kadmon Holdings, Inc. (KDMN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
by Zacks Equity Research
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
Implied Volatility Surging for Kadmon Holdings (KDMN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Kadmon Holdings (KDMN) stock based on the movements in the options market lately.
Kadmon Holdings, Inc. (KDMN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and -42.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kadmon Holdings, Inc. (KDMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kadmon Holdings, Inc. (KDMN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kadmon Holdings, Inc. (KDMN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 37.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for September 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Implied Volatility Surging for Kadmon (KDMN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Kadmon (KDMN) stock based on the movements in the options market lately.
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
by Zacks Equity Research
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moleculin Files New Patents for Cancer Candidate Annamycin
by Zacks Equity Research
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Kadmon Initiates Dosing in Study for Systemic Sclerosis Drug
by Zacks Equity Research
Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).
Will Kadmon Holdings (KDMN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kadmon Holdings (KDMN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kadmon Holdings, Inc. (KDMN).
Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%
by Zacks Equity Research
Kadmon Holdings, Inc. (KDMN) was a big mover last session, as the company saw its shares more than 9% on the day amid huge volumes.
Kadmon Holdings (KDMN) Shares March Higher, Can It Continue?
by Zacks Equity Research
Kadmon Holdings Inc (KDMN) has been on the move lately as the stock has risen by 76.9% in the past four weeks, and it is currently trading well above its 20-Day SMA